关键数据
33.780今开
33.780最高
507.25K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.78%换手率
33.880昨收
32.000最低
13.20M成交额
亏损市盈率静
6.80市净率
0.00%股息率 TTM
-66.38%ROA
33.33052周最高
1.40量比
-100.88M净利润
65.21M总股本
-2.3543每股收益TTM
-2.35Beta
-73.02%ROE
15.51052周最低
5.25%振幅
--毛利率
2.27B总市值
0.56回报/风险
3.53%风险率
Pharvaris NV新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
Pharvaris NV简介
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
公司代码PHVS
公司Pharvaris NV
CEOModig (Berndt B.A.E)
网址https://pharvaris.com/
公司股东
常见问题
Pharvaris NV(PHVS)的当前股价是多少?
Pharvaris NV(PHVS)的当前股价是 32.62。
Pharvaris NV股票的52周最高点是多少?
Pharvaris NV股票的52周最高点是33.33。
Pharvaris NV股票的52周最低点是多少?
Pharvaris NV股票的52周最低点是15.51。
现在Pharvaris NV(PHVS)的股票是买入、持有还是卖出?
根据分析师评级,Pharvaris NV(PHVS)的总体评级为买入,目标价格为47.60。
Pharvaris NV(PHVS)股票的每股收益(EPS TTM)是多少
Pharvaris NV(PHVS)股票的每股收益(EPS TTM)是-3.49。